Last updated: August 12, 2026
Aclovate is the branded version of alclometasone dipropionate, a low- to moderate-potency topical corticosteroid used for inflammatory dermatoses, including eczema and dermatitis. Its commercial profile is mature and genericized. The brand has limited pricing power, no meaningful remaining exclusivity barrier, and no publicly reported standalone revenue. Current value is concentrated in generic volume, formulary access, manufacturing efficiency, and dermatology distribution rather than patent protection.
What is Aclovate and how is it used?
Aclovate contains alclometasone dipropionate 0.05%, a topical corticosteroid available in cream and ointment dosage forms. The FDA label identifies treatment of corticosteroid-responsive dermatoses in adults and pediatric patients, subject to age and duration limitations.[1]
Aclovate product profile
| Attribute |
Aclovate |
| Active ingredient |
Alclometasone dipropionate |
| Strength |
0.05% |
| Drug class |
Topical corticosteroid |
| Common dosage forms |
Cream and ointment |
| Therapeutic area |
Dermatology, inflammatory skin disease |
| Common uses |
Atopic dermatitis, eczema, contact dermatitis |
| FDA pathway |
New drug application originally; subsequent generic ANDA products |
| Current commercial status |
Mature branded and generic market |
| Biosimilar relevance |
None; alclometasone is a small-molecule drug |
Alclometasone dipropionate is generally positioned below high-potency corticosteroids and above low-strength over-the-counter hydrocortisone in prescription dermatology treatment algorithms. Its market is therefore exposed to substitution by both lower-cost steroids and clinically differentiated products such as topical calcineurin inhibitors and nonsteroidal dermatology therapies.
What patents protect Aclovate?
No material unexpired Aclovate patent protection is identified in the FDA Orange Book record for the marketed alclometasone dipropionate products cited in this analysis.[2] The original composition and product patents are long expired.
Patent estate assessment
| Patent category |
Current protection |
| Active-ingredient patent |
Expired |
| Original composition patent |
Expired |
| Cream formulation patent |
No material unexpired Orange Book protection identified |
| Ointment formulation patent |
No material unexpired Orange Book protection identified |
| Method-of-use patent |
No material unexpired Orange Book protection identified |
| Device or delivery patent |
Not material to the marketed products |
| Pediatric exclusivity |
No current exclusivity identified |
| Orphan-drug exclusivity |
Not applicable |
The absence of listed patents does not prevent a company from pursuing non-Orange Book intellectual property involving manufacturing processes, trade secrets, packaging, analytical methods, or privately developed formulations. Those rights do not create the same substitution barrier as an unexpired listed patent covering the approved product.
When did Aclovate lose exclusivity?
Aclovate lost meaningful market exclusivity decades ago. The product is now in the post-exclusivity phase, with competition from multiple abbreviated new drug application products.
FDA approval of generic alclometasone dipropionate products enabled pharmacy-level substitution where state law, payer policy, and prescriber instructions permit it. DailyMed identifies multiple alclometasone dipropionate products across manufacturers and dosage forms.[3]
Exclusivity timeline
| Period |
Commercial event |
Market effect |
| Initial launch period |
Aclovate introduced as a prescription topical corticosteroid |
Brand established clinical and prescriber awareness |
| Patent expiry period |
Original product protection expired |
Generic development became commercially viable |
| Generic entry period |
ANDA products entered the market |
Price competition and substitution increased |
| Current period |
Mature generic dermatology category |
Brand revenue is limited and volume is price sensitive |
There is no current regulatory exclusivity period that would block generic approval for alclometasone dipropionate cream or ointment.
What is the Orange Book status of Aclovate?
Aclovate does not have a commercially important Orange Book patent position based on the cited FDA records. The relevant regulatory issue is generic availability, not patent clearance.
The Orange Book lists approved prescription drug products and, where applicable, patents and exclusivity information submitted for listed drugs.[2] For a mature topical corticosteroid with no listed unexpired patents, an ANDA applicant’s principal challenge is demonstrating pharmaceutical equivalence, bioequivalence or comparative performance as required by FDA, and manufacturing compliance.
Generic approval considerations
Generic applicants must address:
- Active ingredient identity and strength.
- Dosage-form equivalence.
- Inactive-ingredient suitability.
- Product quality and stability.
- Manufacturing controls.
- FDA requirements for topical drug equivalence.
Topical products can present more technical complexity than simple oral tablets because vehicle composition, particle size, rheology, release characteristics, and skin permeation can affect performance. Those issues can raise development costs, but they do not recreate brand exclusivity once generic products are approved.
Are there Paragraph IV challenges to Aclovate?
Paragraph IV litigation is not a material current commercial issue for Aclovate. The product’s principal patents are expired, and no active Orange Book patent dispute is identified in the cited FDA records.
A Paragraph IV certification applies when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. For Aclovate, generic manufacturers have already reached the market through the ordinary post-expiry approval pathway. The practical risk is therefore continued generic price pressure rather than a new wave of patent litigation.
No active settlement agreement affecting generic entry is identified for Aclovate in the cited public FDA sources.
What formulations are protected by Aclovate?
Aclovate’s principal marketed formulations are 0.05% cream and 0.05% ointment. The commercial distinction between these products is based on vehicle characteristics, patient preference, skin location, and disease presentation rather than active patent protection.
Formulation comparison
| Formulation |
Commercial role |
Competitive position |
| Cream 0.05% |
General use, less occlusive vehicle |
Broad generic competition |
| Ointment 0.05% |
More occlusive, often used for dry or thickened lesions |
Generic competition, with vehicle substitution considerations |
| Lotion or other topical formats |
May be marketed by generic manufacturers depending on approval status |
Separate product opportunity, subject to FDA approval |
The cream and ointment products are not interchangeable in every clinical situation. However, the presence of multiple manufacturers reduces the ability of any single supplier to command a substantial premium.
How strong is the Aclovate patent estate?
The Aclovate patent estate is weak from a current commercial-defense perspective because it has no identified active patent barrier and no meaningful regulatory exclusivity. Its residual value is primarily brand recognition and product familiarity.
Patent strength scorecard
| Factor |
Assessment |
| Composition-of-matter protection |
None remaining |
| Formulation protection |
No material listed protection identified |
| Method-of-use protection |
None identified |
| Generic blocking power |
Low |
| Manufacturing complexity |
Low to moderate |
| Switching friction |
Low to moderate |
| Brand recognition |
Moderate in dermatology, limited outside the category |
| Litigation leverage |
Low |
| Licensing value |
Low as a standalone asset |
The most defensible commercial assets are manufacturing know-how, reliable supply, retailer and wholesaler relationships, and any differentiated formulation not covered by the legacy Aclovate label.
What companies compete with Aclovate?
Aclovate competes across two groups: generic alclometasone suppliers and substitute topical corticosteroid products.
Direct generic competitors
Generic alclometasone dipropionate products are marketed by multiple FDA-approved manufacturers and label holders. Product availability can change because suppliers enter, exit, transfer approvals, or experience manufacturing interruptions. The generic market is typically supplied through pharmacy wholesalers, retail pharmacies, Medicaid channels, managed-care formularies, and mail-order distributors.[3]
Therapeutic competitors
| Competitor class |
Examples |
Competitive effect |
| Low-potency topical steroids |
Hydrocortisone products |
Substitute for mild disease and pediatric use |
| Moderate-potency steroids |
Triamcinolone acetonide |
Broad, low-cost alternative |
| Higher-potency steroids |
Betamethasone, fluocinonide |
Substitute for more severe disease |
| Low-potency branded steroids |
Desonide products |
Compete in sensitive-site and pediatric prescribing |
| Nonsteroidal topicals |
Tacrolimus, pimecrolimus, crisaborole, roflumilast |
Reduce steroid exposure in selected patients |
| Newer branded dermatology products |
Topical PDE-4, JAK, and aryl hydrocarbon receptor therapies |
Compete through safety, label breadth, and specialty promotion |
Aclovate’s relative position depends on disease severity, body site, age, payer restrictions, and prescriber preference. Generic triamcinolone is usually the most important broad-market substitute because of its low price and extensive prescribing history.
What is Aclovate’s financial trajectory?
No public company filing cited here reports standalone Aclovate revenue, unit volume, gross margin, or current market share. The financial trajectory is therefore best assessed from product maturity, generic penetration, and category economics.
Revenue trajectory
Aclovate’s likely revenue path follows the standard lifecycle for an older topical prescription product:
- Initial branded growth from physician adoption.
- Revenue erosion after patent expiry and generic entry.
- Continued decline in branded prescriptions as formularies favor generic alclometasone.
- Stabilization at a small residual brand base or transition to generic-only economics.
- Margin pressure from wholesaler discounts, reimbursement compression, and supplier competition.
The branded product’s remaining revenue is likely concentrated in patients whose prescribers, pharmacies, or insurers continue to specify the branded product. That base is structurally vulnerable to generic substitution.
Financial drivers
| Driver |
Impact on Aclovate |
| Generic penetration |
Reduces brand volume and price |
| Formulary tiering |
Determines reimbursement and substitution |
| Retail pharmacy substitution |
Favors lower-cost generic products |
| Supply reliability |
Can temporarily shift market share among generic suppliers |
| Manufacturing cost |
Important to generic margin preservation |
| Dermatology prescribing trends |
Supports category demand but not necessarily brand sales |
| New nonsteroidal therapies |
Creates substitution pressure |
| Pediatric and sensitive-site demand |
Supports clinical relevance for selected patients |
A generic manufacturer can still generate acceptable returns if it has efficient production, stable API supply, competitive contracting, and limited manufacturing competition. Those returns are usually volume-driven and do not resemble protected-brand pharmaceutical margins.
What generic entry risks exist for Aclovate?
Generic entry risk is already realized rather than prospective. The central commercial risk is ongoing price erosion and commoditization.
Generic launch scenarios
| Scenario |
Likely outcome |
| Stable supplier base |
Gradual price compression with predictable availability |
| New low-cost entrant |
Faster reimbursement and wholesale price erosion |
| Supply disruption |
Temporary price increases or share shifts for remaining suppliers |
| Brand withdrawal |
Generic products absorb most prescriptions |
| New differentiated topical |
Share loss in selected disease segments |
A new generic entrant would not need to overcome a meaningful patent barrier. Its main hurdles would be FDA approval, manufacturing validation, commercial contracting, and achieving sufficient scale in a low-value category.
What FDA regulatory status applies to Aclovate?
Aclovate is an FDA-approved prescription topical corticosteroid product. Generic alclometasone dipropionate products are approved through the ANDA pathway when they meet FDA requirements for pharmaceutical equivalence and therapeutic equivalence.[1][2]
The regulatory environment is mature. There is no biologic license application, biosimilar pathway, or interchangeability designation relevant to alclometasone dipropionate. Regulatory risk centers on manufacturing quality, product consistency, labeling, adverse-event reporting, and supply continuity.
Are licensing deals or settlements affecting Aclovate?
No major current licensing transaction or generic-entry settlement is identified in the cited public FDA sources. The asset has limited strategic licensing value because its core patent estate has expired and the active ingredient is available through multiple generic products.
Potential transaction value would be higher for a portfolio buyer acquiring:
- Several dermatology products together.
- Established pharmacy and managed-care contracts.
- Manufacturing capacity.
- A differentiated topical vehicle.
- A broader branded dermatology sales platform.
Aclovate alone is unlikely to justify a significant licensing premium unless combined with manufacturing, distribution, or portfolio synergies.
How does Aclovate compare with newer dermatology drugs?
Aclovate has a cost advantage and long clinical familiarity. Newer dermatology products compete through nonsteroidal mechanisms, broader chronic-use positioning, improved safety narratives, or specialty reimbursement strategies.
| Attribute |
Aclovate |
Newer branded nonsteroidal topicals |
| Active ingredient |
Alclometasone dipropionate |
PDE-4, JAK, or other agents |
| Generic competition |
Extensive |
Usually limited during exclusivity |
| Price |
Low to moderate |
High |
| Steroid exposure |
Yes |
No |
| Chronic-use positioning |
Restricted by steroid considerations |
Often broader, depending on label |
| Payer access |
Generally favorable for generic |
Prior authorization often required |
| Commercial growth potential |
Low |
Higher if clinical differentiation is strong |
Aclovate remains relevant where physicians want an established topical steroid with moderate potency at a low cost. It has limited growth potential because clinical demand does not translate into branded pricing power.
What is the geographic coverage of Aclovate?
The principal commercial market is the United States, where FDA approval, Orange Book listing, prescription substitution, and generic ANDA competition determine market structure. Alclometasone dipropionate may also be marketed internationally under different brand names, dosage forms, or regulatory classifications.
Geographic value depends on:
- Local patent and data-exclusivity rules.
- National reimbursement systems.
- Prescription versus over-the-counter classification.
- Local dermatology prescribing patterns.
- Generic manufacturing and import requirements.
- Distributor and pharmacy concentration.
The U.S. market is the most relevant for Orange Book and Paragraph IV analysis. International rights require separate country-by-country review.
Key Takeaways
- Aclovate is alclometasone dipropionate 0.05%, a mature prescription topical corticosteroid.
- The product has no identified material unexpired Orange Book patent or regulatory exclusivity.
- Generic competition is established, making price and formulary access more important than patent protection.
- No current Paragraph IV dispute or generic-entry settlement is identified in the cited FDA records.
- Standalone Aclovate revenue and market share are not publicly reported.
- Brand revenue has likely followed a long-term decline after generic entry.
- Generic manufacturers compete through cost, supply reliability, contracting, and distribution.
- The main competitive threats are generic alclometasone, triamcinolone, hydrocortisone, desonide, and newer nonsteroidal dermatology products.
- Biosimilar risk is irrelevant because alclometasone dipropionate is a small molecule.
- The asset has low standalone licensing value but may retain portfolio value within a broader dermatology business.
FAQs
Is Aclovate still available by prescription?
Yes. Aclovate and generic alclometasone dipropionate products are prescription topical corticosteroids, subject to manufacturer and pharmacy availability.
Is generic alclometasone dipropionate therapeutically equivalent to Aclovate?
FDA-approved generic products may receive therapeutic-equivalence designations when they meet applicable approval requirements. Pharmacy substitution remains subject to state law, payer rules, and prescriber instructions.[2]
Does Aclovate have a pediatric exclusivity period?
No current pediatric exclusivity period is identified. Pediatric use is addressed in the FDA labeling, including age-specific warnings and administration limitations.[1]
Can a company launch a new alclometasone dipropionate generic without licensing the Aclovate brand?
A company generally does not need a brand license to develop an ANDA product after relevant patents and exclusivities have expired. It must obtain FDA approval and comply with applicable labeling, manufacturing, and quality requirements.
Is alclometasone dipropionate a high-potency steroid?
No. Alclometasone dipropionate is generally classified as a low- to moderate-potency topical corticosteroid, depending on the formulation, site of application, and classification system used.
References
-
U.S. Food and Drug Administration. (n.d.). Aclovate (alclometasone dipropionate) cream and ointment prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
National Library of Medicine. (n.d.). DailyMed: Alclometasone dipropionate topical products. U.S. National Library of Medicine.
